
EquitySector - HealthcareVery High Risk
Regular
NAV (05-Dec-25)
Returns (Since Inception)
Fund Size
₹4,131 Cr
Expense Ratio
1.93%
ISIN
INF200K01446
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
31 Dec 2004
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-0.55%
+0.57% (Cat Avg.)
3 Years
+23.46%
+21.99% (Cat Avg.)
5 Years
+17.72%
+16.40% (Cat Avg.)
10 Years
+11.32%
+13.46% (Cat Avg.)
Since Inception
+15.24%
— (Cat Avg.)
| Equity | ₹3,958.02 Cr | 95.82% |
| Debt | ₹2.85 Cr | 0.07% |
| Others | ₹169.88 Cr | 4.11% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹494.53 Cr | 11.97% |
| Divi's Laboratories Ltd | Equity | ₹284.99 Cr | 6.90% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹232.56 Cr | 5.63% |
| Cipla Ltd | Equity | ₹183.76 Cr | 4.45% |
| Treps | Cash - Repurchase Agreement | ₹177.72 Cr | 4.30% |
| Lupin Ltd | Equity | ₹174.9 Cr | 4.23% |
| Lonza Group Ltd ADR | Equity | ₹165.52 Cr | 4.01% |
| Acutaas Chemicals Ltd | Equity | ₹165.38 Cr | 4.00% |
| Torrent Pharmaceuticals Ltd | Equity | ₹148.82 Cr | 3.60% |
| Laurus Labs Ltd | Equity | ₹144.39 Cr | 3.50% |
| Fortis Healthcare Ltd | Equity | ₹137.87 Cr | 3.34% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹134.22 Cr | 3.25% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹132.4 Cr | 3.21% |
| Biocon Ltd | Equity | ₹127.47 Cr | 3.09% |
| Gland Pharma Ltd | Equity | ₹123.17 Cr | 2.98% |
| Aether Industries Ltd | Equity | ₹122.81 Cr | 2.97% |
| Mankind Pharma Ltd | Equity | ₹121.55 Cr | 2.94% |
| Abbott India Ltd | Equity | ₹120.3 Cr | 2.91% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹119.89 Cr | 2.90% |
| Poly Medicure Ltd | Equity | ₹116.35 Cr | 2.82% |
| Alkem Laboratories Ltd | Equity | ₹113.7 Cr | 2.75% |
| Concord Biotech Ltd | Equity | ₹102.07 Cr | 2.47% |
| Aurobindo Pharma Ltd | Equity | ₹85.87 Cr | 2.08% |
| Anthem Biosciences Ltd | Equity | ₹82.51 Cr | 2.00% |
| Cohance Lifesciences Ltd | Equity | ₹67.73 Cr | 1.64% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹59.88 Cr | 1.45% |
| Pfizer Ltd | Equity | ₹49.75 Cr | 1.20% |
| Medplus Health Services Ltd | Equity | ₹40.44 Cr | 0.98% |
| Gufic Biosciences Ltd | Equity | ₹35.57 Cr | 0.86% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹34.95 Cr | 0.85% |
| Sudeep Pharma Ltd | Equity | ₹29.82 Cr | 0.72% |
| Net Receivable / Payable | Cash - Collateral | ₹-7.84 Cr | 0.19% |
| Rainbow Childrens Medicare Ltd | Equity | ₹4.86 Cr | 0.12% |
| India (Republic of) | Bond - Short-term Government Bills | ₹2.85 Cr | 0.07% |
Large Cap Stocks
39.73%
Mid Cap Stocks
17.66%
Small Cap Stocks
31.70%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹3,669.84 Cr | 88.84% |
| Basic Materials | ₹288.18 Cr | 6.98% |
Standard Deviation
This fund
14.09%
Cat. avg.
16.00%
Lower the better
Sharpe Ratio
This fund
1.15
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better
Since June 2011
ISIN INF200K01446 | Expense Ratio 1.93% | Exit Load No Charges | Fund Size ₹4,131 Cr | Age 20 years 11 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹12,62,149 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Regular
NAV (05-Dec-25)
Returns (Since Inception)
Fund Size
₹4,131 Cr
Expense Ratio
1.93%
ISIN
INF200K01446
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
31 Dec 2004
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-0.55%
+0.57% (Cat Avg.)
3 Years
+23.46%
+21.99% (Cat Avg.)
5 Years
+17.72%
+16.40% (Cat Avg.)
10 Years
+11.32%
+13.46% (Cat Avg.)
Since Inception
+15.24%
— (Cat Avg.)
| Equity | ₹3,958.02 Cr | 95.82% |
| Debt | ₹2.85 Cr | 0.07% |
| Others | ₹169.88 Cr | 4.11% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹494.53 Cr | 11.97% |
| Divi's Laboratories Ltd | Equity | ₹284.99 Cr | 6.90% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹232.56 Cr | 5.63% |
| Cipla Ltd | Equity | ₹183.76 Cr | 4.45% |
| Treps | Cash - Repurchase Agreement | ₹177.72 Cr | 4.30% |
| Lupin Ltd | Equity | ₹174.9 Cr | 4.23% |
| Lonza Group Ltd ADR | Equity | ₹165.52 Cr | 4.01% |
| Acutaas Chemicals Ltd | Equity | ₹165.38 Cr | 4.00% |
| Torrent Pharmaceuticals Ltd | Equity | ₹148.82 Cr | 3.60% |
| Laurus Labs Ltd | Equity | ₹144.39 Cr | 3.50% |
| Fortis Healthcare Ltd | Equity | ₹137.87 Cr | 3.34% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹134.22 Cr | 3.25% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹132.4 Cr | 3.21% |
| Biocon Ltd | Equity | ₹127.47 Cr | 3.09% |
| Gland Pharma Ltd | Equity | ₹123.17 Cr | 2.98% |
| Aether Industries Ltd | Equity | ₹122.81 Cr | 2.97% |
| Mankind Pharma Ltd | Equity | ₹121.55 Cr | 2.94% |
| Abbott India Ltd | Equity | ₹120.3 Cr | 2.91% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹119.89 Cr | 2.90% |
| Poly Medicure Ltd | Equity | ₹116.35 Cr | 2.82% |
| Alkem Laboratories Ltd | Equity | ₹113.7 Cr | 2.75% |
| Concord Biotech Ltd | Equity | ₹102.07 Cr | 2.47% |
| Aurobindo Pharma Ltd | Equity | ₹85.87 Cr | 2.08% |
| Anthem Biosciences Ltd | Equity | ₹82.51 Cr | 2.00% |
| Cohance Lifesciences Ltd | Equity | ₹67.73 Cr | 1.64% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹59.88 Cr | 1.45% |
| Pfizer Ltd | Equity | ₹49.75 Cr | 1.20% |
| Medplus Health Services Ltd | Equity | ₹40.44 Cr | 0.98% |
| Gufic Biosciences Ltd | Equity | ₹35.57 Cr | 0.86% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹34.95 Cr | 0.85% |
| Sudeep Pharma Ltd | Equity | ₹29.82 Cr | 0.72% |
| Net Receivable / Payable | Cash - Collateral | ₹-7.84 Cr | 0.19% |
| Rainbow Childrens Medicare Ltd | Equity | ₹4.86 Cr | 0.12% |
| India (Republic of) | Bond - Short-term Government Bills | ₹2.85 Cr | 0.07% |
Large Cap Stocks
39.73%
Mid Cap Stocks
17.66%
Small Cap Stocks
31.70%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹3,669.84 Cr | 88.84% |
| Basic Materials | ₹288.18 Cr | 6.98% |
Standard Deviation
This fund
14.09%
Cat. avg.
16.00%
Lower the better
Sharpe Ratio
This fund
1.15
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better
Since June 2011
ISIN INF200K01446 | Expense Ratio 1.93% | Exit Load No Charges | Fund Size ₹4,131 Cr | Age 20 years 11 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹12,62,149 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments